(Q34603644)

English

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

scientific article

Statements

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (English)
Michael W Schuster
Dina Ben-Yehuda
Anthony L Boral
Anthony A Amato
16 January 2009

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit